
Centene (CNC) Stock Forecast & Price Target
Centene (CNC) Analyst Ratings
Bulls say
Centene is supported by a broad, defensible footprint in government-sponsored care, with about 20 million medical members and leadership in Medicaid, plus meaningful exposure to Medicare, Marketplace, and PDP. Management’s raised 2026 adjusted EPS guidance and the reiterated expectation of margin recovery reflect improving Medicaid rate adequacy, stabilizing cost trends, and stronger Marketplace pricing after 100% repricing, while PDP membership growth and MA progress add further earnings support. Long-term, the company’s 30-state Medicaid scale, D-SNP overlap, and constructive CMS/rate-setting backdrop create multiple avenues for compounding earnings, even as near-term Medicaid acuity and Marketplace volatility remain temporary headwinds.
Bears say
Centene is exposed to structural pressure from government-sponsored healthcare dependence, with Medicaid roughly 64% of 20 million medical members and recurring vulnerability to OBBBA-driven federal funding cuts, work requirements, and redeterminations. Its fundamentals are further weakened by a persistent rate-to-acuity mismatch, as 2025 ended at about a -1% pre-tax margin and Medicaid trend ran in the mid-6% range against mid-4% rate assumptions, while membership is expected to decline about 6% from year-end 2025 to year-end 2026. Earnings quality is also pressured by Marketplace morbidity, elevated utilization in behavioral health and high-cost drugs, and PDP margin compression from above 3% in 2025 to about 2% in 2026 as risk corridors normalize.
This aggregate rating is based on analysts' research of Centene and is not a guaranteed prediction by Public.com or investment advice.
Centene (CNC) Analyst Forecast & Price Prediction
Start investing in Centene (CNC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Centene (CNC) Forecast
Centene (CNC) Analyst Forecast & Price Prediction
Start investing in Centene (CNC)
Order type
Buy in
Order amount
Est. shares
0 shares